<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <meta name="description" content="Evidence-based clinical management of Preterm Premature Rupture of Membranes (PPROM)">
    <title>PPROM: Clinical Management Update</title>
    
    <!-- Reveal.js CSS -->
    <link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/reveal.js@5.0.4/dist/reset.css">
    <link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/reveal.js@5.0.4/dist/reveal.css">
    
    <!-- Custom Theme -->
    <link rel="stylesheet" href="theme.css">
</head>
<body>
    <div class="reveal">
        <div class="slides">
            
            <!-- Slide 1: Title -->
            <section>
                <h1>Preterm Premature Rupture<br>of Membranes</h1>
                <p class="subtitle">Evidence-Based Management</p>
                <div class="title-footer">
                    ACOG/SMFM Clinical Update<br>
                    Maternal-Fetal Medicine
                </div>
            </section>

            <!-- Slide 2: Objectives -->
            <section>
                <h2>Learning Objectives</h2>
                <div class="content-box">
                    <ul>
                        <li class="fragment">Recognize PPROM epidemiology and pathophysiology</li>
                        <li class="fragment">Apply evidence-based diagnostic criteria</li>
                        <li class="fragment">Implement GA-specific management protocols</li>
                        <li class="fragment">Counsel on maternal and fetal risks</li>
                        <li class="fragment">Navigate areas of clinical uncertainty</li>
                    </ul>
                </div>
            </section>

            <!-- Slide 3: Epidemiology -->
            <section>
                <h2>Epidemiology</h2>
                <div class="stat">3%</div>
                <div class="stat-label">of all pregnancies</div>
                <div class="stat fragment" style="font-size: 5rem; margin-top: 2rem;">30-40%</div>
                <div class="stat-label fragment">of preterm births</div>
            </section>

            <!-- Slide 4: Pathophysiology -->
            <section>
                <h2>Pathophysiology</h2>
                <div class="two-column">
                    <div class="column fragment">
                        <h3>Membrane Failure</h3>
                        <ul>
                            <li>Matrix metalloproteinases</li>
                            <li>Collagen degradation</li>
                            <li>Inflammatory mediators</li>
                            <li>Mechanical stress</li>
                        </ul>
                    </div>
                    <div class="column fragment">
                        <h3>Infection Link</h3>
                        <ul>
                            <li>Bidirectional relationship</li>
                            <li>Cause or consequence</li>
                            <li>Ascending pathway risk</li>
                        </ul>
                    </div>
                </div>
            </section>

            <!-- Slide 5: Risk Factors -->
            <section>
                <h2>Risk Factors</h2>
                <h3>Strong Evidence</h3>
                <div class="content-box">
                    <ul>
                        <li class="fragment">Prior PPROM (recurrence 16-32%)</li>
                        <li class="fragment">Vaginal bleeding in pregnancy</li>
                        <li class="fragment">Cigarette smoking</li>
                        <li class="fragment">Short cervical length (&lt;25mm)</li>
                        <li class="fragment">Intraamniotic infection</li>
                    </ul>
                </div>
            </section>

            <!-- Slide 6: Clinical Diagnosis -->
            <section>
                <h2>Diagnosis: Clinical Triad</h2>
                <div class="evidence-box">
                    <h3>Sterile Speculum Exam <span class="evidence-level level-a">Level A</span></h3>
                    <ul>
                        <li class="fragment"><strong>Pooling:</strong> Amniotic fluid in posterior fornix</li>
                        <li class="fragment"><strong>Nitrazine:</strong> pH &gt;6.5 (caution: false positives)</li>
                        <li class="fragment"><strong>Ferning:</strong> Microscopic crystallization pattern</li>
                    </ul>
                </div>
                <div class="warning-box fragment">
                    <strong>Avoid digital cervical exam</strong> unless labor/delivery imminent
                </div>
            </section>

            <!-- Slide 7: Ancillary Tests -->
            <section>
                <h2>When Diagnosis Unclear</h2>
                <div class="content-box">
                    <h3>Commercial Tests</h3>
                    <ul>
                        <li class="fragment"><strong>AmniSure (PAMG-1):</strong> Sens 98-99%, Spec 87-100%</li>
                        <li class="fragment"><strong>ROM Plus (IGFBP-1/AFP):</strong> Moderate accuracy</li>
                        <li class="fragment"><strong>Ultrasound:</strong> Oligohydramnios supports but not diagnostic</li>
                    </ul>
                </div>
            </section>

            <!-- Slide 8: Management Overview -->
            <section>
                <h2>Management by Gestational Age</h2>
                <div class="timeline">
                    <div class="timeline-item fragment">
                        <div class="timeline-ga">16-22⁶</div>
                        <div class="timeline-text">Periviable<br>Counseling-centered</div>
                    </div>
                    <div class="timeline-item fragment">
                        <div class="timeline-ga">23-31⁶</div>
                        <div class="timeline-text">Expectant<br>ABX + Steroids</div>
                    </div>
                    <div class="timeline-item fragment">
                        <div class="timeline-ga">32-33⁶</div>
                        <div class="timeline-text">Transition<br>Consider delivery</div>
                    </div>
                    <div class="timeline-item fragment">
                        <div class="timeline-ga">34⁰-36⁶</div>
                        <div class="timeline-text">Delivery<br>at 34 weeks</div>
                    </div>
                </div>
            </section>

            <!-- Slide 9: Periviable PPROM -->
            <section>
                <h2>Periviable PPROM (16-22⁶ weeks)</h2>
                <div class="consensus-box">
                    <h3>Counseling-Centered Approach <span class="evidence-level level-c">Consensus</span></h3>
                    <ul>
                        <li class="fragment">GA-specific survival and morbidity data</li>
                        <li class="fragment">Pulmonary hypoplasia risk (10-26%)</li>
                        <li class="fragment">Maternal risks (infection, retained placenta)</li>
                        <li class="fragment">Offer expectant vs. delivery options</li>
                    </ul>
                </div>
                <div class="warning-box fragment">
                    <strong>No corticosteroids</strong> at this gestational age
                </div>
            </section>

            <!-- Slide 10: Antibiotics -->
            <section>
                <h2>Latency Antibiotics</h2>
                <div class="protocol-box">
                    <h3>NICHD MFMU Protocol <span class="evidence-level level-a">Level A</span></h3>
                    <div class="dose fragment">
                        IV ampicillin 2g Q6h + IV erythromycin 250mg Q6h × 48h
                    </div>
                    <div class="fragment" style="text-align: center; margin: 1rem 0; font-size: 2rem;">↓</div>
                    <div class="dose fragment">
                        PO amoxicillin 250mg Q8h + PO erythromycin 333mg Q8h × 5d
                    </div>
                </div>
                <div class="warning-box fragment">
                    <strong>Avoid amoxicillin-clavulanate</strong> — associated with NEC
                </div>
            </section>

            <!-- Slide 11: Corticosteroids -->
            <section>
                <h2>Antenatal Corticosteroids</h2>
                <div class="evidence-box">
                    <h3>Strong Evidence for Benefit <span class="evidence-level level-a">Level A</span></h3>
                    <div class="protocol-box steroid-box">
                        <div class="dose fragment">Betamethasone 12mg IM Q24h × 2 doses</div>
                        <div class="fragment" style="text-align: center; margin: 1rem 0;">OR</div>
                        <div class="dose fragment">Dexamethasone 6mg IM Q12h × 4 doses</div>
                    </div>
                    <ul class="fragment">
                        <li><strong>Indication:</strong> 23-34 weeks (some use through 36⁶)</li>
                        <li><strong>Reduces:</strong> RDS, IVH, NEC, neonatal mortality</li>
                    </ul>
                </div>
            </section>

            <!-- Slide 12: Magnesium Sulfate -->
            <section>
                <h2>Neuroprotection</h2>
                <div class="evidence-box">
                    <h3>Magnesium Sulfate <span class="evidence-level level-a">Level A</span></h3>
                    <div class="protocol-box neuro-box">
                        <div class="dose fragment">4-6g loading dose, then 1-2g/hr maintenance</div>
                    </div>
                    <ul class="fragment">
                        <li><strong>Indication:</strong> Delivery anticipated &lt;32 weeks</li>
                        <li><strong>Benefit:</strong> Reduces cerebral palsy risk and severity</li>
                    </ul>
                </div>
            </section>

            <!-- Slide 13: Delivery at 34 Weeks -->
            <section>
                <h2>Late Preterm PPROM (34-36⁶ weeks)</h2>
                <div class="key-point">
                    Delivery recommended at 34⁰ weeks
                </div>
                <div class="evidence-box fragment">
                    <h3>PPROMT Trial Evidence <span class="evidence-level level-a">Level A</span></h3>
                    <ul>
                        <li>Reduces chorioamnionitis</li>
                        <li>Reduces neonatal infection</li>
                        <li>No increase in neonatal morbidity</li>
                    </ul>
                </div>
            </section>

            <!-- Slide 14: Delivery Indications -->
            <section>
                <h2>Indications for Delivery</h2>
                <div class="content-box">
                    <ul>
                        <li class="fragment"><span class="highlight">Chorioamnionitis</span> (fever, tenderness, fetal tachycardia)</li>
                        <li class="fragment"><span class="highlight">Non-reassuring fetal status</span></li>
                        <li class="fragment"><span class="highlight">Placental abruption</span> (bleeding, pain)</li>
                        <li class="fragment"><span class="highlight">Advanced labor</span></li>
                        <li class="fragment"><span class="highlight">≥34 weeks gestation</span></li>
                    </ul>
                </div>
            </section>

            <!-- Slide 15: Maternal Risks -->
            <section>
                <h2>Maternal Risks</h2>
                <div class="grid-3">
                    <div class="metric-card fragment">
                        <div class="metric-label">Chorioamnionitis</div>
                        <div class="metric-value">13-60%</div>
                        <small>↑ with early GA, ↑ latency</small>
                    </div>
                    <div class="metric-card fragment">
                        <div class="metric-label">Abruption</div>
                        <div class="metric-value">4-12%</div>
                        <small>Higher than baseline</small>
                    </div>
                    <div class="metric-card fragment">
                        <div class="metric-label">Cord Prolapse</div>
                        <div class="metric-value">1-2%</div>
                        <small>↑ with oligohydramnios</small>
                    </div>
                </div>
                <div class="content-box fragment">
                    <ul style="font-size: 1.3rem;">
                        <li>Endometritis, sepsis (rare but serious)</li>
                        <li>Increased cesarean delivery risk</li>
                        <li>Recurrence risk in subsequent pregnancies</li>
                    </ul>
                </div>
            </section>

            <!-- Slide 16: Fetal/Neonatal Risks -->
            <section>
                <h2>Fetal/Neonatal Risks</h2>
                <div class="two-column">
                    <div class="column fragment">
                        <h3>Immediate</h3>
                        <ul>
                            <li>Neonatal sepsis/pneumonia</li>
                            <li>Cord compression/prolapse</li>
                            <li>Malpresentation</li>
                            <li>Placental abruption</li>
                        </ul>
                    </div>
                    <div class="column fragment">
                        <h3>Prematurity-Related</h3>
                        <ul>
                            <li>RDS, BPD</li>
                            <li>IVH, PVL</li>
                            <li>NEC</li>
                            <li>ROP</li>
                            <li>Long-term neurodevelopmental</li>
                        </ul>
                    </div>
                </div>
            </section>

            <!-- Slide 17: Pulmonary Hypoplasia -->
            <section>
                <h2>Pulmonary Hypoplasia</h2>
                <div class="warning-box">
                    <h3 style="color: #E74C3C;">Periviable PPROM-Specific Risk</h3>
                    <ul>
                        <li class="fragment"><strong>Incidence:</strong> 10-26% with PPROM &lt;24 weeks</li>
                        <li class="fragment"><strong>Risk factors:</strong> Rupture &lt;20 weeks, severe prolonged oligohydramnios</li>
                        <li class="fragment"><strong>Outcome:</strong> Often lethal or severe respiratory compromise</li>
                    </ul>
                </div>
            </section>

            <!-- Slide 18: Counseling - Initial -->
            <section>
                <h2>Initial Counseling</h2>
                <div class="content-box">
                    <ul>
                        <li class="fragment"><strong>What happened:</strong> "Protective bag of water" has broken early</li>
                        <li class="fragment"><strong>Timing:</strong> Most deliver within 1 week; some longer latency</li>
                        <li class="fragment"><strong>Management:</strong> Hospitalization, antibiotics, steroids, monitoring</li>
                        <li class="fragment"><strong>Risks:</strong> Infection, preterm birth complications</li>
                        <li class="fragment"><strong>Signs to report:</strong> Fever, pain, foul discharge, bleeding, contractions</li>
                    </ul>
                </div>
            </section>

            <!-- Slide 19: Counseling - GA-Specific -->
            <section>
                <h2>GA-Specific Counseling</h2>
                <table>
                    <thead>
                        <tr>
                            <th>Gestational Age</th>
                            <th>Key Counseling Points</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr class="fragment">
                            <td><strong>Periviable</strong></td>
                            <td>Full outcomes discussion; option for expectant vs. delivery; shared decision-making</td>
                        </tr>
                        <tr class="fragment">
                            <td><strong>23-32 weeks</strong></td>
                            <td>Each week improves outcomes; goal to reach 34 weeks; NICU course likely</td>
                        </tr>
                        <tr class="fragment">
                            <td><strong>34-36 weeks</strong></td>
                            <td>Excellent survival; delivery recommended at 34 weeks; may have mild respiratory issues</td>
                        </tr>
                    </tbody>
                </table>
            </section>

            <!-- Slide 20: Controversies - Timing -->
            <section>
                <h2>Areas of Controversy</h2>
                <h3>Timing of Delivery (32-34 weeks)</h3>
                <div class="consensus-box">
                    <ul>
                        <li class="fragment"><strong>Established:</strong> Delivery at 34 weeks superior to expectant management</li>
                        <li class="fragment"><strong>Uncertain:</strong> Optimal timing between 32-34 weeks</li>
                        <li class="fragment"><strong>Current practice:</strong> Varies by institution</li>
                    </ul>
                </div>
            </section>

            <!-- Slide 21: Controversies - Outpatient -->
            <section>
                <h2>Areas of Controversy</h2>
                <h3>Outpatient Management</h3>
                <div class="consensus-box">
                    <ul>
                        <li class="fragment"><strong>Traditional:</strong> Hospitalization until delivery</li>
                        <li class="fragment"><strong>Evolving:</strong> Selected outpatient candidates after stabilization</li>
                        <li class="fragment"><strong>Uncertain:</strong> Patient selection criteria, GA limits, safety protocols</li>
                        <li class="fragment"><strong>Current:</strong> Most favor inpatient, especially &lt;32 weeks</li>
                    </ul>
                </div>
            </section>

            <!-- Slide 22: Controversies - Steroids Late Preterm -->
            <section>
                <h2>Areas of Controversy</h2>
                <h3>Corticosteroids 34-36 Weeks</h3>
                <div class="consensus-box">
                    <ul>
                        <li class="fragment"><strong>ALPS trial:</strong> Betamethasone reduces respiratory morbidity 34-36⁶ weeks</li>
                        <li class="fragment"><strong>ACOG guidance:</strong> Recommends for women at risk of delivery within 7 days</li>
                        <li class="fragment"><strong>Question:</strong> Does this apply to PPROM when delivery recommended at 34 weeks?</li>
                    </ul>
                </div>
            </section>

            <!-- Slide 23: Controversies - Amniocentesis -->
            <section>
                <h2>Areas of Controversy</h2>
                <h3>Amniocentesis for Infection Assessment</h3>
                <div class="consensus-box">
                    <ul>
                        <li class="fragment"><strong>Potential:</strong> Could identify subclinical intraamniotic infection</li>
                        <li class="fragment"><strong>Challenges:</strong> Technical difficulty with oligohydramnios; unclear impact on management</li>
                        <li class="fragment"><strong>Current practice:</strong> Not routinely performed; rely on clinical signs</li>
                    </ul>
                </div>
            </section>

            <!-- Slide 24: Evidence Summary -->
            <section>
                <h2>Evidence Summary</h2>
                <div class="evidence-box">
                    <h3><span class="evidence-level level-a">Level A</span> Strong Evidence (RCT/Meta-analysis)</h3>
                    <ul>
                        <li class="fragment">Latency antibiotics prolong pregnancy, reduce morbidity</li>
                        <li class="fragment">Corticosteroids reduce RDS, IVH, NEC</li>
                        <li class="fragment">Magnesium sulfate reduces cerebral palsy &lt;32 weeks</li>
                        <li class="fragment">Delivery at 34 weeks superior to expectant management</li>
                    </ul>
                </div>
                <div class="consensus-box fragment">
                    <h3><span class="evidence-level level-c">Level C</span> Consensus-Based</h3>
                    <ul>
                        <li>Inpatient vs. outpatient management</li>
                        <li>Antenatal testing protocols</li>
                        <li>Periviable PPROM counseling and management</li>
                    </ul>
                </div>
            </section>

            <!-- Slide 25: Key Takeaways -->
            <section>
                <h2>Clinical Pearls</h2>
                <div class="content-box">
                    <ul>
                        <li class="fragment">PPROM accounts for 30-40% of preterm births</li>
                        <li class="fragment">Diagnosis primarily clinical; avoid digital exams</li>
                        <li class="fragment">Antibiotics and steroids are evidence-based interventions</li>
                        <li class="fragment">Deliver at 34 weeks; expectant management before</li>
                        <li class="fragment">Infection risk increases with latency but balanced against prematurity</li>
                        <li class="fragment">Counseling must be GA-specific and individualized</li>
                    </ul>
                </div>
            </section>

            <!-- Slide 26: Summary -->
            <section>
                <h2>Summary</h2>
                <div class="key-point fragment">
                    PPROM management balances risks of prematurity against risks of infection and oligohydramnios
                </div>
                <div class="content-box fragment">
                    <ul>
                        <li>Evidence-based interventions: antibiotics, corticosteroids, magnesium sulfate</li>
                        <li>GA-specific protocols optimize outcomes</li>
                        <li>Shared decision-making essential for periviable cases</li>
                        <li>Ongoing research addresses areas of uncertainty</li>
                    </ul>
                </div>
            </section>

            <!-- Slide 27: References -->
            <section>
                <h2>References</h2>
                <div class="content-box references">
                    <p class="fragment"><strong>ACOG Practice Bulletin No. 217:</strong> Prelabor Rupture of Membranes. Obstet Gynecol. 2020.</p>
                    <p class="fragment"><strong>ACOG Committee Opinion No. 713:</strong> Antenatal Corticosteroid Therapy for Fetal Maturation. Obstet Gynecol. 2017.</p>
                    <p class="fragment"><strong>ACOG Committee Opinion No. 455:</strong> Magnesium Sulfate Before Anticipated Preterm Birth for Neuroprotection. Obstet Gynecol. 2010 (Reaffirmed 2020).</p>
                    <p class="fragment"><strong>Morris JM et al.</strong> Immediate delivery vs expectant management after preterm prelabour rupture of the membranes close to term (PPROMT trial). Lancet. 2016.</p>
                    <p class="fragment"><strong>Mercer BM et al.</strong> Antibiotic therapy for reduction of infant morbidity after preterm premature rupture of the membranes. JAMA. 1997.</p>
                </div>
            </section>

        </div>
    </div>

    <!-- Reveal.js Scripts -->
    <script src="https://cdn.jsdelivr.net/npm/reveal.js@5.0.4/dist/reveal.js"></script>
    
    <script>
        // Initialize Reveal.js
        Reveal.initialize({
            // Display controls
            controls: true,
            controlsBackArrows: 'visible',
            
            // Display a presentation progress bar
            progress: true,
            
            // Display slide number
            slideNumber: 'c/t',
            
            // Push each slide change to the browser history
            history: true,
            
            // Enable keyboard shortcuts
            keyboard: true,
            
            // Enable the slide overview mode
            overview: true,
            
            // Vertical centering of slides
            center: true,
            
            // Enable touch navigation on devices with touch input
            touch: true,
            
            // Loop the presentation
            loop: false,
            
            // Fragments
            fragments: true,
            
            // Flags whether to include the current fragment in the URL
            fragmentInURL: true,
            
            // Transition style
            transition: 'slide', // none/fade/slide/convex/concave/zoom
            
            // Transition speed
            transitionSpeed: 'default', // default/fast/slow
            
            // Transition style for full page slide backgrounds
            backgroundTransition: 'fade',
            
            // Responsive
            width: '100%',
            height: '100%',
            margin: 0.04,
            minScale: 0.2,
            maxScale: 2.0
        });
    </script>
</body>
</html>
